It’s a Miracle

December 16, 2024

DENVER, Colo., Dec 16, 2024 (247marketnews.com)- Nature’s Miracle (NASDAQ: NMHI), Siyata Mobile (NASDAQ: SYTA), Webuy (NASDAQ: WBUY), Viridian Therapeutics (NASDAQ: VRDN), HeartBeam (NASDAQ: BEAT), and Sidus Space (NASDAQ:SIDU).

Nature’s Miracle (NASDAQ: NMHI) agreed to acquire a 90% equity interest in J&Y Marigold, which is currently developing a Bitcoin mining facility with anticipated power load of 14 megawatts (“MW”), for an aggregate purchase price of up to $5.32 million.

James Li, Chairman and CEO of Nature’s Miracle, commented, “Our acquisition of a majority stake in J&Y Marigold marks an important milestone in strengthening our Bitcoin mining vertical, a transformative step in our journey toward diversification and growth. We expect the 14 MW Bitcoin mining facility being built by J&Y Marigold to be operational in the first half of 2025, enabling us to leverage advanced infrastructure to deliver efficient and scalable mining capabilities. This strategic acquisition allows us to expand beyond our core focus on agriculture technologies and solidify our foundation in the cryptocurrency industry. The global cryptocurrency market is experiencing unprecedented growth, fueled by increasing adoption and heightened institutional interest. Bitcoin mining, in particular, serves as a critical component in maintaining blockchain network security and stability while offering significant economic opportunities. This acquisition represents a vital step in our broader strategy to foster diversified growth, enhance operational capabilities, and seize new opportunities in a fast-evolving global landscape.”

In the world of high frequency trading and neck braking stock market moves, if one can silence the noise and read the tea leaves, there is no easier layup than when a company tells you a wealth creation event is on the horizon.

Siyata Mobile (NASDAQ: SYTA) plans on hosting a Press Conference, this month, to cover an “Important Corporate Development” and considering that some of Siyata’s recent accomplishments, the event must be something special.

Some of Siyata’s recent events that weren’t big enough to warrant a press conference include * Record revenue growth, as SYTA more than tripled its year-over-year third quarter revenue * Achieving stocked status at top carriers, including AT&T (NYSE: T) and T-Mobile (NASDAQ: TMUS), a key business milestone that’s typically reserved for device leaders like Apple (NASDAQ: AAPL), Samsung, LG, and Sony (NYSE: SONY), which set a new 52-week high of $22.71.

  • With its reported outstanding share count being approximately 4.1 million, yesterday’s volume indicates that the average share already passed hands more than 7 times, or that there is a massive short that could squeeze.
  • Considering that many shareholders are probably excited to learn about this development, it’s hard to believe that most shareholders sold and if that’s the case, the shares available to flip can’t address the volume needed to cover the shorted shares.
  • Logic dictates that the shorters are expecting to be bailed out, again, as when Siyata was midstream in its stocked status efforts it was forced to issue additional shares to pay to reach the other side, but that’s no longer the case.

Siyata’s improved fundamentals includes its new shareholder friendly $7 million equity line of credit (ELOC) that allows Siyata to incrementally access capital, which minimizes dilution and preserves shareholder value, by removing the shorter bailout mechanism.

“Siyata is in the best position it’s been in since our company’s inception, as our capital expenditures have directly improved all performance metrics, and we look forward to delivering continued successful results. Please tune into our upcoming press conference, which will highlight a next level shareholder value creation event that you surely won’t want to miss,” said Marc Seelenfreund, Siyata’s CEO.

If my short thesis is wrong, shareholders should still see upside from the new initiative unveiling, but if my short thesis is right, there’s some resistance to almost the $3 range, then the volume weighted resistance appears to jump to around $12 and nearly $25.

Webuy (NASDAQ: WBUY) stated that it moved forward to the next phase of NVIDIA’s AI Accelerator Program, confirming Webuy’s commitment to leveraging AI technologies to enhance its offerings and deliver customer value.

The NVIDIA AI Accelerator Program is supported by Singapore’s Economic Development Board, Tribe (an Asian blockchain accelerator), and the Digital Industry Singapore, which provides startups and businesses with access to NVIDIA’s state-of-the-art computing resources and technical expertise.

Vincent Xue Bin, Webuy Global’s CEO and Co-Founder, stated, “We are thrilled to advance to the next stage of NVIDIA’s AI Accelerator Program. This achievement reflects our dedication to integrating AI-driven solutions into our platform to create unparalleled customer experiences. We look forward to exploring new possibilities with NVIDIA’s support.”

Viridian Therapeutics (NASDAQ: VRDN) reported positive topline data from the THRIVE-2 phase 3 clinical trial, which met all primary and secondary endpoints at the 15-week primary analysis timepoint after five infusions of veligrotug, showing statistically significant responses on all of the measured signs and symptoms of chronic thyroid eye disease (TED), and was generally well-tolerated with 94% of patients completing their treatment course

Steve Mahoney, Viridian’s President and CEO, commented, “We are extremely pleased to announce better-than-expected THRIVE-2 results generated in the broadest population of chronic TED patients studied in a global phase 3 study to date. We believe that these efficacy and safety results in only five infusions, combined with our compelling data from THRIVE, confirm the potential of veli to be the treatment-of-choice for all forms of active and chronic TED.

HeartBeam (NASDAQ: BEAT) stated that the US Food and Drug Administration (FDA) granted the HeartBeam system 510(k) clearance for comprehensive arrhythmia assessment and the Company will initiate an Early Access Program to gain vital patient and physician feedback, in preparation for commercial launch.

The HeartBeam device is a high-fidelity electrocardiogram (ECG) system that captures heart signals from three distinct directions for actionable heart health information and is the first-of-its-kind to receive FDA clearance.

Robert Eno, HeartBeam’s CEO, commented, “It’s well documented that patients who delay seeking care for their cardiac symptoms face worse clinical outcomes. The ability for patients to capture high-fidelity ECG signals from three directions wherever they are when symptoms occur will help patients get the care they need in a timelier manner. The FDA clearance of our technology is a significant milestone for the Company that brings us one step closer to fulfilling our vision of providing unprecedented cardiac insights to individuals and physicians.”

To view HeartBeam System video

MoBot alerted Sidus Space (NASDAQ:SIDU) in this morning’s premarket at $1.74 and it’s traded as high as $2.70 in the premarket and $2.46, after the opening bell. For more information on Sidus, please visit www.sidusspace.com.

Please go to 247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data.

24/7 Market News disclosure

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (NMHI, SYTA, WBUY, VRDN, BEAT, SIDU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.